Protective efficacy of Zika vaccine in AG129 mouse model

Scientific Reports

Volumn 7, Issue , 2017, Pages

  Sumathy, K ^a   Kulkarni, Bharathi ^a   Gondu, Ravi Kumar ^a   Ponnuru, Sampath Kumar ^a   Bonguram, Nagaraju ^a   Eligeti, Rakesh ^a   Gadiyaram, Sindhuja ^a   Praturi, Usha ^a   Chougule, Bhushan ^a   Karunakaran, Latha ^a   Ella, Krishna M ^a  

^a Bharat Biotech International Ltd   (India)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN; VIRUS VACCINE;

ANIMAL; DISEASE MODEL; IMMUNOLOGY; MOUSE; TREATMENT OUTCOME; ZIKA FEVER; ZIKA VIRUS;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DISEASE MODELS, ANIMAL; MICE; TREATMENT OUTCOME; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES; ZIKA VIRUS; ZIKA VIRUS INFECTION;

EID: 85017429616     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep46375     Document Type: Article

References (40)

1. Mlakar, J. et al. Zika virus associated with microcephaly. N. Engl. J. Med. 374, 951-958 (2016).
2. Rasmussen, S. A. et al. Zika virus and birth defects-reviewing the evidence for causality. N. Engl. J. Med. 374, 1981-1987 (2016).
3. Costello, A. et al. Defining the syndrome associated with congenital Zika virus infection. Bull. World. Health. Organ. 94, 406-406A (2016).
4. Li, D. et al. Zika virus disrupts neural progenitor development and leads to microcephaly in mice. Cell Stem Cell 19, 120-126 (2016).
5. Cugola, F. R. et al. The Brazilian Zika virus strain causes birth defects in experimental models. Nature 534, 267-271 (2016).
6. Parra, B. et al. Guillain-Barré syndrome associated with Zika virus infection in Colombia. N. Engl. J. Med. 375, 1513-1523 (2016).
7. Brasil, P. et al. Guillain-Barré syndrome associated with Zika virus infection. Lancet 387, 1482 (2016).
8. Cao-Lormeau, V. M. et al. Guillain-Barré syndrome outbreak associated with Zika virus infection in French Polynesia: a casecontrol study. Lancet 387, 1531-1539 (2016).
9. Dos Santos, T. et al. Zika virus and the Guillain-Barre syndrome - case series from seven countries. N. Engl. J. Med. 375, 1598-1601 (2016).
10. Dirlikov, E. et al. Guillain-Barré syndrome during ongoing Zika virus transmission-Puerto Rico, January 1-July 31, 2016. MMWR Morb. Mortal. Wkly. Rep. 65, 910-914 (2016).
11. Bogoch, I. I. et al. Potential for Zika virus introduction and transmission in resource-limited countries in Africa and the Asia-Pacific region: a modelling study. Lancet Infect. Dis. 16, 1237-1245 (2016).
12. Hombach, J., Friede, M., Moorthy, V., Costello, A. & Kieny, M. P. Developing a vaccine against Zika. The BMJ. 355, i5923 (2016).
13. Thomas, S. J., L'Azou, M., Barrett, A. D. & Jackson, N. A. Fast-track Zika vaccine development - is it possible? N. Eng. J. Med. 375, 1212-1216 (2016).
14. Barrett, A. D. T. Zika vaccine candidates progress through nonclinical development and enter clinical trials. Npj Vaccines 1, 16023 (2016).
15. Abbink, P. et al. Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. Science 353, 1129-1132 (2016).
16. Dowd, K. A. et al. Rapid development of a DNA vaccine for Zika virus. Science 354, 237-240 (2016).
17. Larocca, R. A. et al. Vaccine protection against Zika virus from Brazil. Nature 536, 474-478 (2016).
18. Aliota, M. T. et al. Characterization of lethal Zika virus infection in AG129 mice. PLoS. Negl. Trop. Dis. 10, e0004682 (2016).
19. Zompi, S., Santich, B. H., Beatty, P. R. & Harris, E. Protection from secondary dengue virus infection in a mouse model reveals the role of serotype cross-reactive B and T cells. J. Immunol. 188, 404-416 (2016).
20. Zhu, J., Huang, X. & Yang, Y. Type I interferon signaling in both B and CD4 T cells is required for protective antibody response to adenovirus. J. Immunol. 178, 3505-3510 (2007).
21. Fuchs, J. et al. Investigating the efficacy of monovalent and tetravalent dengue vaccine formulations against DENV-4 challenge in AG129 mice. Vaccine 32, 6537-6543 (2014).
22. Partidos, C. D. et al. Probing the attenuation and protective efficacy of a candidate chikungunya virus vaccine in mice with compromised interferon (IFN) signaling. Vaccine 29, 3067-3073 (2011).
23. Dick, G. W. A., Kitchen, S. F. & Haddow, A. J. Zika virus. I. Isolations and serological specificity. Trans. R. Soc. Trop. Med. Hyg. 46, 509-520 (1952).
24. Haddow, A. D. et al. Genetic characterization of Zika virus strains: geographic expansion of the Asian lineage. PLoS. Negl. Trop. Dis. 6, e1477 (2012).
25. Faye, O. et al. Molecular evolution of Zika virus during its emergence in the 20(th) century. PLoS. Negl. Trop. Dis. 8, e2636 (2014).
26. Dai, L. et al. Structures of the Zika virus envelope protein and its complex with a flavivirus broadly protective antibody. Cell Host Microbe 19, 696-704 (2016).
27. Maurer-Stroh, S. et al. South-east Asian Zika virus strain linked to cluster of cases in Singapore, August 2016. Euro Surveill. 21, 30347 (2016).
28. Dowd, K. A. et al. Broadly neutralizing activity of Zika virus-immune sera identifies a single viral serotype. Cell Reports 16, 1485-1491 (2016).
29. Aliota, M. T. et al. Heterologous protection against Asian Zika virus challenge in rhesus macaques. PLoS. Negl. Trop. Dis. 10, e0005168 (2016).
30. Beasley, D. W., McAuley, A. J. & Bente, D. A. Yellow fever virus: genetic and phenotypic diversity and implications for detection, prevention and therapy. Antiviral. Res. 115, 48-70 (2015).
31. Orlinger, K. K. et al. A tick-borne encephalitis virus vaccine based on the European prototype strain induces broadly reactive crossneutralizing antibodies in humans. J. Infect. Dis. 203, 1556-1564 (2011).
32. Holzmann, H. et al. Molecular epidemiology of tick-borne encephalitis virus: cross-protection between European and Far Eastern subtypes. Vaccine 10, 345-349 (1992).
33. Tsarev, S. A., Sanders, M. L., Vaughn, D. W. & Innis, B. L. Phylogenetic analysis suggests only one serotype of Japanese encephalitis virus. Vaccine 18 Suppl 2, 36-43 (2000).
34. Beasley, D. W. et al. Protection against Japanese encephalitis virus strains representing four genotypes by passive transfer of sera raised against ChimeriVax-JE experimental vaccine. Vaccine 22, 3722-3726 (2004).
35. Dick, G. W. Zika virus. II. Pathogenicity and physical properties. Trans. R. Soc. Trop. Med. Hyg. 46, 521-34 (1952).
36. Hombach, J., Solomon, T., Kurane, I., Jacobson, J. & Wood, D. Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004. Vaccine 23, 5205-5211 (2005).
37. Barba-Spaeth, G. et al. Structural basis of potent Zika-dengue virus antibody cross-neutralization. Nature 536, 48-53 (2016).
38. Dejnirattisai, W. et al. Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with Zika virus. Nat. Immunol. 17, 1102-1108 (2016).
39. Lanciotti, R. S. et al. Genetic and Serologic Properties of Zika Virus Associated with an Epidemic, Yap State, Micronesia, 2007. Emerg. Infect. Dis. 14(8), 1232-1239 (2008).
40. Stettler, K. et al. Specificity, cross-reactivity and function of antibodies elicited by Zika virus infection. Science 353, 823-826 (2016).